Nirogacestat

Major

Nirogacestat Clindamycin ANTIROBE Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Omeprazole Gastrobim Explained Reduced nirogacestat/CYP2C19 substrate exposure and reduced efficacy of nirogacestat/CYP2C19 substrate Details Nirogacestat Colchicine Colcrys Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Abemaciclib Verzenio Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Acalabrutinib Calquence Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Nirogacestat Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Nirogacestat Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Nirogacestat Axitinib Inlyta Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Bedaquiline Sirturo Increased bedaquiline exposure Details Nirogacestat Bosutinib Bosulif Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Brexpiprazole Rexulti Increased brexpiprazole exposure Details Nirogacestat Brigatinib Alunbrig Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Clindamycin Injection ANTIROBE Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Clindamycin Topical C/T/S® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Clindamycin Vaginal Cleocin Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Cobimetinib Cotellic Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Cyclosporine Injection Atopica Increased nirogacestat/CYP3A substrate exposure and an increased risk of nirogacestat/CYP3A substrate-related adverse effects Details Nirogacestat Cyclosporine Ophthalmic Cequa Increased nirogacestat/CYP3A substrate exposure and an increased risk of nirogacestat/CYP3A substrate-related adverse effects Details Nirogacestat Dasatinib Phyrago Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Dexlansoprazole Dexilant Reduced nirogacestat/CYP2C19 substrate exposure and reduced efficacy of nirogacestat/CYP2C19 substrate Details Nirogacestat Dihydroergotamine Injection DHE-45® Injection Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Dihydroergotamine Nasal Spray Migranal Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Docetaxel Beizray Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Docetaxel Injection Beizray Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Dofetilide Tikosyn Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Nirogacestat Encorafenib Braftovi Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions, reduced sensitive CYP3A4 substrate exp... Details Nirogacestat Entrectinib Rozlytrek Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Esomeprazole Nexium Reduced nirogacestat exposure and reduced efficacy of nirogacestat Details Nirogacestat Esomeprazole Injection Nexium Reduced nirogacestat exposure and reduced efficacy of nirogacestat Details Nirogacestat Everolimus Afinitor Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Famotidine Calmicid Reduced nirogacestat exposure and reduced efficacy of nirogacestat Details Nirogacestat Famotidine Injection Calmicid Reduced nirogacestat exposure and reduced efficacy of nirogacestat Details Nirogacestat Fentanyl Transdermal Patch Duragesic® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Nirogacestat Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Nirogacestat Ketoconazole Topical Extina® Foam Increased nirogacestat exposure and an increased risk of nirogacestat-related adverse effects Details Nirogacestat Lansoprazole Prevacid Reduced nirogacestat/CYP2C19 substrate exposure and reduced efficacy of nirogacestat/CYP2C19 substrate Details Nirogacestat Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased strong and moderate CYP3A4 in... Details Nirogacestat Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details